1-3 of 3
Iris Sison
Close
Sort by
Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Genevive H. Hernandez, John So, Kathryn A. Logronio, Maya F. Kotturi, Won Seog Kim, Philippe Armand, Chan Y. Cheah, Ajay K. Gopal, Ian W. Flinn, Gareth P. Gregory, Matthew J. Matasar, Loretta J. Nastoupil, Catherine S. Diefenbach, Sung-Soo Yoon, Matthew Ku, Ibrahim Qazi, Maya K. Leabman, Iris Sison, Bruce A. Keyt, Chris H. Takimoto, Thomas J. Manley, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 6436–6438.
https://doi.org/10.1182/blood-2022-163235
Published: 2022
Journal Articles

A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

Elizabeth Budde, Ajay K Gopal, Won Seog Kim, Ian W. Flinn, Chan Yoon Y. Cheah, Loretta Nastoupil, Matthew J. Matasar, Catherine S. Diefenbach, Gareth P Gregory, Ibrahim Qazi, Ching-Fai Pang, Maya Leabman, Genevive Hernandez, Iris Sison, Bruce A. Keyt, Daniel Chen, Philippe Armand
Journal: Blood
Blood (2021) 138 (Supplement 1): 132.
https://doi.org/10.1182/blood-2021-153355
Published: 2021
Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

Elizabeth Budde, MDPhD, Ajay K. Gopal, MD, Ian W. Flinn, MD PhD, Loretta J. Nastoupil, MD, Michael S. Gordon, MD, Ching-Fai Pang, PhD, Bruce Keyt, PhD, Steve Carroll, PhD, Maya Leabman, PhD, Genevive Hernandez, PhD, Iris Sison, Daniel Chen, MD PhD, Wayne Godfrey, MD, Philippe Armand, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134983
Published: 2020